Healthcare shares
Of the 7 healthcare shares Kinzan tracks, 1 are higher and 6 lower over the last 24 hours as of 22:38 UTC on 23 October 2026; ABBV leads at +0.2% and LLY trails at −2.5%.
Pharmaceutical manufacturers, insurers and biotechnology, where regulation and patents matter more than the economic cycle.
24-hour moves
Ranked within the group
All 7
| Instrument | Price | 24h | 24-hour chart | 20d vol | Surprise |
|---|---|---|---|---|---|
| Eli Lilly LLY | $1,273.46 | −2.5% | 1.82% | −1.4σ | |
| UnitedHealth UNH | $418.09 | −1.6% | 1.72% | −0.9σ | |
| Johnson & Johnson JNJ | $263.81 | −1.4% | 1.82% | −0.8σ | |
| Merck MRK | $145.27 | −1.3% | 1.85% | −0.7σ | |
| Pfizer PFE | $30.03 | −1.3% | 1.21% | −1.1σ | |
| AbbVie ABBV | $285.64 | +0.2% | 1.38% | +0.1σ | |
| Novo Nordisk NVO | $39.05 | −1.0% | 1.25% | −0.8σ |
Healthcare has historically been the defensive sector, on the reasoning that demand for treatment does not fall when the economy does. That reputation holds less firmly than it used to, because so much of the sector's recent performance has turned on a small number of drug franchises whose success or failure moves individual members violently in opposite directions. Two things drive pharmaceutical names that drive nothing else on this board. The first is the patent cliff: revenue from a successful drug is protected for a defined period and then collapses as generics enter, so the expiry calendar is known years ahead and the question is always what replaces it. The second is binary event risk, where a trial result or a regulatory decision reprices a company in a single session by an amount no economic data could. Policy is the sector-wide input. Government pricing negotiations and reimbursement rules apply across the group, which is why healthcare can move as a block on political news while its individual businesses have nothing in common.